Order results by:
| Issue | Title | |
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| "... of clopidogrel play an important role in the resistance development. Allel variants of the gene cytochrome CYP2C ..." | ||
| Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
| "... The clinical significance of CYP2C19 genetic polymorphism, associated with the violation ..." | ||
| Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
| S. J. Martsevich | ||
| "... The ACC/AHA clopidogrel clinical alert about the possibility of ineffective treatment ..." | ||
| Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
| A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
| "... Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization ..." | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... for resistance to antiplatelet therapy with clopidogrel. The decrease in the effectiveness of prolonged therapy ..." | ||
| Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
| "... of carriership of at least one CYP4F2*3 allele on the risk of resistance to clopidogrel in patients with acute ..." | ||
| Vol 8, No 1 (2012) | RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION | Abstract similar documents |
| V. A. Sulimov, E. V. Moroz | ||
| "... Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance ..." | ||
| Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
| "... .1 in the CYP2C19*1/*1 group vs 18.2±16.4 in the CYP2C19*1/*2 one (р=0.03). Clopidogrel laboratory resistance (P ..." | ||
| Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
| "... Среди причин резистентности к антитромбоцитарным препаратам выделяют клинические, клеточные и ..." | ||
| Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
| "... Aim. To study a rate of clopidogrel use in patients having indications for clopidogrel therapy ..." | ||
| Vol 8, No 2 (2012) | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev | ||
| "... Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel ..." | ||
| Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
| E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
| "... Aim. To study a rate of resistance to acetylsalicylic acid (ASA) and clopidogrel and clinical ..." | ||
| Vol 7, No 1 (2011) | THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS | Abstract similar documents |
| O. V. Gaisenok | ||
| "... in patients with cardioascular diseases are discussed. Role of clopidogrel in contemporary antiplatelet ..." | ||
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... , warfarin, ticlopidine and clopidogrel are discussed. Study data on new antiplatelet drugs are given ..." | ||
| Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
| "... antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and clopidogrel by optical aggregometry in patients ..." | ||
| Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
| Vol 6, No 2 (2010) | THE MODERN ASPECTS OF CLOPIDOGREL USE | Abstract similar documents |
| E. N. Dankovtseva, D. A. Zateyshchikov | ||
| "... The possibilities and evidence base of clopidogrel use in clinical practice are discussed. Data ..." | ||
| Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
| L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
| "... Aim. To analyze the literary and own data about clopidogrel influence on platelets during ..." | ||
| Vol 5, No 5 (2009) | EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi | ||
| "... and morphology of erythrocytes and to assess their changes during therapy with acetylsalicylic acid, emclopidogrel/em ..." | ||
| Vol 13, No 5 (2017) | INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION | Abstract similar documents |
| E. V. Tavlueva, A. V. Alekseenko, O. V. Gruzdeva, O. L. Barbarash | ||
| "... Aim. To study the effect of replacing emclopidogrel/em with ticagrelor on endpoints of hospital period ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... + emclopidogrel/em) can be prescribed to elderly patients with cardiovascular comorbidity who are deemed unsuitable ..." | ||
| Vol 4, No 2 (2008) | ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
| D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov | ||
| "... Aim. To evaluate the incidence of acetylsalicylic acid (ASA) and emclopidogrel/em resistance ..." | ||
| Vol 11, No 1 (2015) | EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Andreev, D. A. Sychev | ||
| "... of emclopidogrel/em, the association of residual platelet reactivity with clinical outcomes and a review ..." | ||
| Vol 7, No 1 (2011) | THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY | Abstract similar documents |
| V. V. Yakusevich, A. S. Petrochenko, V. A. Simonov, N. Yu. Levshin, A. D. Deev | ||
| "... Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original emclopidogrel/em ..." | ||
| Vol 10, No 6 (2014) | СONCOMITANT ADMINISTRATION OF CLOPIDOGREL AND PROTON PUMP INHIBITORS: ARE THERE ANY OPEN QUESTIONS LEFT TODAY? | Abstract similar documents |
| S. Yu. Martsevich, A. Yu. Suvorov | ||
| "... Concomitant administration of emclopidogrel/em and proton pump inhibitors (PPI), the possible influence ..." | ||
| Vol 19, No 3 (2023) | Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski | ||
| "... . The risk of HRPR to emclopidogrel/em is higher in 681A emCYP/em2C19 allele carriers compared to the G681 carriers ..." | ||
| Vol 14, No 2 (2018) | DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT | Abstract similar documents |
| N. В. Perepech, A. V. Tregubov | ||
| "... . 51.8% of respondents recommend a combination of acetylsalicylic acid and emclopidogrel/em ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... as between the groups of clopidogrelsensitive and emclopidogrel/em-resistant patients. No association between ..." | ||
| Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| M. Yu. Gilyarov, Е. V. Konstantinova | ||
| "... of reperfusion and the selected treatment strategy. Due to some limitations in the use of emclopidogrel/em ..." | ||
| Vol 8, No 2 (2012) | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS | Abstract similar documents |
| A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova | ||
| "... Aim. To compare effects of acetylsalicylic acid (ASA) and two emclopidogrel/em drugs on residual ..." | ||
| Vol 15, No 3 (2019) | Study of the Association of V640L (rs6133) Polymorphism in the Platelet P-selectin Gene with Acetylsalicylic Acid Resistance in Patients after Coronary Bypass Surgery | Abstract similar documents |
| A. A. Kosinova, T. S. Mongush, M. D. Goncharov, T. N. Subbotina, K. S. Semashchenko, G. Y. Kochmareva, Yu. I. Grinshtein | ||
| "... +emclopidogrel/em (75 mg/day). The aggregation study was performed with an optical aggregometer, using 5 μM ..." | ||
| Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
| "... and induced flow cytofluorometry during antiplatelet therapy with emclopidogrel/em and acetylsalicylic acid (ASA ..." | ||
| Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
| T. M. Uskach, A. S. Tereshchenko | ||
| "... pronounced platelet inhibition than emclopidogrel/em. The drugs differ in pharmacodynamics and platelet reactivity ..." | ||
| Vol 7, No 5 (2011) | HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY | similar documents |
| G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Sciascio | ||
| "... Введение. Полученные ранее данные свидетельствуют о наличии у emклопидогрела/em не только ..." | ||
| Vol 12, No 5 (2016) | Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome | Abstract similar documents |
| I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova | ||
| "... with ASA and emclopidogrel/em, risk of thrombotic events is saved in ASA resistant patients with ACS ..." | ||
| Vol 14, No 6 (2018) | P2Y12 Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel | Abstract PDF (Eng) similar documents |
| N. M. Vorobyeva | ||
| "... with emclopidogrel/em or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves ..." | ||
| Vol 11, No 2 (2015) | CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE | Abstract similar documents |
| K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva | ||
| "... antiplatelet drugs (acetylsalicylic acid and emclopidogrel/em) and heparin. There were not any reasons ..." | ||
| Vol 5, No 6 (2009) | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, A. R. Kiselev, Ya. P. Dovgalevsky | ||
| "... антиагрегантной терапии. emРезистентность/em к АСК констатировали в случае сохранения на фоне ее приема суммарного ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... (3.8%) patients. Aspirin was the only antiplatelet agent in 3 cases and emclopidogrel/em – in one case ..." | ||
| Vol 13, No 4 (2017) | GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS | Abstract similar documents |
| M. A. Vorobyeva, M. M. Azova, O. O. Gigani, I. V. Garmash, S. V. Villevalde, Zh. D. Kobalava | ||
| "... , 62.1% of men) were included into the study. Polymorphism Phe189Ser of the emCYP/em3A4 (gene encoding ..." | ||
| Vol 10, No 5 (2014) | DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov | ||
| "... .8% of patients also received combination of emclopidogrel/em and acetylsalicylic acid, but changed medicinal products ..." | ||
| Vol 14, No 6 (2018) | Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation | Abstract PDF (Eng) similar documents |
| A. E. Imaeva, Yu. A. Balanova, A. V. Kontsevaya, A. V. Kapustina, D. V. Duplyakov, O. H. Malysheva, I. V. Osipova, T. A. Petrichko, G. I. Kropanin, R. A. Kasimov, D. A. Leon, M. McKee | ||
| "... pharmacies. Among antiplatelet agents, aspirin was available in most pharmacies, and emclopidogrel/em was mostly ..." | ||
| Vol 5, No 6 (2009) | ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS | Abstract similar documents |
| N. A. Dmitrieva, S. N. Tolpygina | ||
| Vol 18, No 5 (2022) | The Problem of Drug Interactions Between Rosuvastatin and Ticagrelor in the Aspect of the Risk of Rhabdomyolysis: Discussion of the Problem and Description of the Clinical Case | Abstract similar documents |
| O. V. Gaisenok, Yu. M. Chichkov, M. V. Leonova | ||
| "... Background. Combination therapy with two antiplatelet agents (ticagrelor or emclopidogrel/em plus ..." | ||
| Vol 11, No 4 (2015) | EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. V. Rudakova, N. V. Lomakin | ||
| "... Dual antiplatelet therapy, including emclopidogrel/em and aspirin, in a significant share of patients ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... antithrombotic therapy, preference should be given to emclopidogrel/em compared to other, more powerful P2Y12 ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... antiplatelet therapy with acetyl salicylic acid and emclopidogrel/em. Numerous clinical characteristics ..." | ||
| Vol 16, No 2 (2020) | LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period | Abstract similar documents |
| S. Yu. Martsevich, A. V. Zagrebelnyy, N. P. Zolotareva, N. P. Kutishenko, Yu. V. Lukina, M. L. Ginzburg, D. A. Startsev, S. V. Blagodatskikh | ||
| "... of use of acetylsalicylic acid, emclopidogrel/em, statins, beta-blockers, ACE inhibitors, angiotensin II ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... ), encoding P-glycoprotein, in pharmacotherapy with digoxin, antiplatelet drugs (emclopidogrel/em tikagrelol ..." | ||
| Vol 9, No 1 (2013) | OUTPATIENT REGISTER OF CARDIOVASCULAR DISEASES IN THE RYAZAN REGION (RECVASA): PRINCIPAL TASKS, EXPERIENCE OF DEVELOPMENT AND FIRST RESULTS | Abstract PDF (Eng) similar documents |
| S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, M. M. Lukyanov, N. N. Nikulina, A. V. Zagrebelny, A. N. Vorobyov, K. G. Pereverseva, E. A. Pravkina, A. D. Deev, E. Yu. Andreenko, A. I. Ershova, A. N. Meshkov, R. P. Myasnikov, S. E. Serdyuk, М. S. Kharlap | ||
| "... : antiplatelet agents – in 60.4% of the cases (584 patients received acetylsalicylic acid and 20 – emclopidogrel/em ..." | ||
| Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
| L. A. Haisheva, S. V. Shlyk | ||
| "... of revealed disorders with antiplatelet agent — emclopidogrel/em 75 mg/day. Material and methods. 40 patients ..." | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| "... четырех профилактических групп, показанных к приему пациентам, перенесшим инфаркт миокарда (emантиагреганты/em ..." | ||
| Vol 7, No 3 (2011) | STROKE PREVENTION IN INTERNIST PRACTICE | Abstract similar documents |
| D. A. Napalkov, A. V. Zhilenko | ||
| "... требованиями современных рекомендаций. Современная фармакотерапия включает emантиагреганты/em или антикоагулянты ..." | ||
| Vol 18, No 4 (2022) | The effect of rs776746 polymorphism in the CYP3A5 gene on heart rate when using bisoprolol in patients with acute coronary syndrome | Abstract similar documents |
| V. A. Shumkov, K. A. Zagorodnikova, S. A. Boldueva, A. A. Murzina | ||
| "... Aim. The aim of this work was to study the occurrence of the rs776746 allelic variant of the emCYP/em3A ..." | ||
| Vol 14, No 4 (2018) | Role of Single Nucleotide Polymorphism of СУР17А Gene in the Development of Stroke | Abstract similar documents |
| S. Yu. Nikulina, V. A. Shulman, A. A. Chernova, D. A. Nikulin, A. A. Semenchukov, O. V. Marilovceva, S. S. Tret'jakova, I. I. Lebedeva, V. N. Maksimov | ||
| "... emCYP/em17A1 is one of the many genes that can participate in the formation of predisposition ..." | ||
| Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
| "... is emclopidogrel/em. It has been proven that the use of emclopidogrel/em to date not always reduces the risk of development ..." | ||
| Vol 9, No 3 (2013) | TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN | Abstract similar documents |
| A. I. Martynov, E. V. Akatova, I. V. Urlayeva, O. P. Nicolin | ||
| "... . emРезистентность/em к аспирину может снизить эффективность лечения, именно поэтому данный вопрос обращает на себя все ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... пациентов с хронической ИБС. Основное внимание уделено emантиагрегантам/em и антикоагулянтам. Обсуждены ..." | ||
| Vol 17, No 4 (2021) | Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery | Abstract similar documents |
| T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Zh. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. A. Grishina, D. A. Sychev | ||
| "... therapy in patients with emCYP/em2C9*2 (430CT) rs179985 and emCYP/em2C9*3 (1075AC) rs1057910 gene polymorphisms ..." | ||
| Vol 20, No 3 (2024) | Use of glycoprotein IIb/IIIa inhibitors in myocardial infarction in the Russian Federation, according to the Russian Registry of Acute Myocardial Infarction REGION-IM | Abstract similar documents |
| N. S. Kostritca, R. M. Rabinovich, R. M. Shakhnovich, I. S. Yavelov, R. G. Gulyan, Yu. K. Rytova, S. N. Tereschenko, A. D. Erlikh, D. V. Pevzner | ||
| Vol 7, No 6 (2011) | PHARMACOTHERAPY ANALYSIS OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION IN HOSPITALS OF VARIOUS TYPES | Abstract similar documents |
| R. M. Magdeev, O. V. Reshetko, E. Y. Rudnichenko, N. V. Furman, P. V. Dolotovskaya, T. Y. Grozdova, L. N. Volkova | ||
| "... , and emclopidogrel/em was not prescribed. At the same hospital clotting time was determined for monitoring of heparin ..." | ||
| Vol 7, No 6 (2011) | CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM | Abstract similar documents |
| Yu. F. Salakhova, S. V. Gar'kina, T. V. Kislukhin, D. V. Duplyakov, V. S. Ivanov, E. R. Perunova, E. I. Bazhenova, S. E. Burnazyan, S. M. Khokhlunov | ||
| "... therapy (acetylsalicylic acid, emclopidogrel/em, warfarin) was made on the 4th day of disease onset taking ..." | ||
| Vol 12, No 5 (2016) | Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms | Abstract PDF (Eng) similar documents |
| Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev | ||
| "... Aim. To evaluate treatment adherence and prevalence of emCYP/em2C9 and VKORC1 gene mutations ..." | ||
| Vol 14, No 1 (2018) | NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Ju. P. Skirdenko, N. A. Nikolayev | ||
| "... , polymorphism of genes emCYP/em2C9 and VKORC1 and the structure of food preferences. Results. Persons ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| Vol 3, No 2 (2007) | VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY | Abstract similar documents |
| D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes | ||
| "... of polymorphisms of genes of their biotransformation (emCYP/em2C9) and molecule-targets (VKORC1). This created basis ..." | ||
| Vol 17, No 1 (2021) | Pharmacogenetics as a Way for Personalizing Diuretic Therapy: Focus on Torasemide | Abstract similar documents |
| N. M. Gafurova, E. V. Shikh, O. D. Ostroumova | ||
| "... B1 polymorphism is approximately 15.5%, the emCYP/em2C9 polymorphism is 20%, and the OAT1 and OAT4 ..." | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... Aim. The aim of our study was to investigate the influence of polymorphic markers of emCYP/em3A4*22 emCYP/em ..." | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... of emCYP/em2C9 and VKORC1 genes mutations were determined at the initial examination. These indicators were ..." | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... metabolized by emCYP/em3A4 with minor contributions from emCYP/em1A2, emCYP/em2C8, emCYP/em2C9, emCYP/em2C19 and emCYP/em2J2 isoenzymes ..." | ||
| Vol 15, No 3 (2019) | Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population | Abstract similar documents |
| K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko, D. A. Sychev | ||
| "... ", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «emCYP/em2C19 ..." | ||
| Vol 12, No 3 (2016) | CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH ISCHEMIC HEART DISEASE RESISTANT TO ACETYLSALICYLIC ACID IN PERIOPERATIVE PERIOD OF CORONARY ARTERY BYPASS GRAFT: RESULTS OF AN OPEN PROSPECTIVE STUDY | Abstract PDF (Eng) similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein, A. V. Kovalev, V. G. Sukhovol'skiy, A. A. Savchenko | ||
| "... emрезистентности/em к АСК составила 26,7%. У резистентных к АСК пациентов по сравнению с чувствительными к АСК ..." | ||
| Vol 10, No 6 (2014) | PROGNOSTIC IMPACT OF COMMUNITY-ACQUIRED AND HOSPITAL-ACQUIRED HYPONATREMIA IN PATIENTS WITH DECOMPENSATED HEART FAILURE | Abstract similar documents |
| D. Yu. Shchekochikhin, Ph. Yu. Kopylov, N. L. Kozlovskaya, A. L. Syrkin | ||
| "... исход, необходимость перевода в отделение интенсивной терапии, развитие emрезистентности/em к петлевым ..." | ||
| Vol 17, No 1 (2021) | Aspirin Resistance as a Result of Impaired Interaction of Platelets and Neutrophils in Patients with Coronary Heart Disease | Abstract similar documents |
| M. D. Goncharov, A. A. Savchenko, Yu. I. Grinshtein, I. I. Gvozdev, A. A. Kosinova, T. S. Mongush | ||
| "... кишечнорастворимой формы АСК в дозе 100 мг/сут. emРезистентность/em к АСК определяли на оптическом агрегометре при уровне ..." | ||
| Vol 2, No 3 (2006) | CLINICAL SIGNIFICANCE OF ASPIRIN RESISTANCE IN PATIENTS WITH CARDIO-VASCULAR DISEASES | Abstract similar documents |
| P. J. Dovgalevsky, N. V. Furman, N. F. Puchinian | ||
| "... на фоне терапии аспирином или emрезистентность/em к аспирину является независимым предиктором высокого ..." | ||
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... in trials and proven efficacy in the prevention of stroke/systemic embolism, the use of emclopidogrel/em ..." | ||
| Vol 11, No 6 (2015) | Nephrogenic factors of resistance to antihypertensive treatment in patients with essential hypertension | Abstract similar documents |
| N. V. Teplova, V. A. Lyusov, R. G. Oganov, E. M. Evsikov, R. A. Sharipov, M. H. Zhapoeva, E. G. Kurumlidu | ||
| Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
| N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
| "... агрегации оценивали с помощью лазерного агрегометра. emРезистентность/em к АСК констатировали, если на фоне ..." | ||
| Vol 9, No 6 (2013) | THROMBOLYSIS OR PRIMARY PCI FOR MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION? THE STREAM TRIAL (STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION) | Abstract similar documents |
| V. A. Sulimov | ||
| "... by half in patients aged ≥75 years) in combination with emclopidogrel/em and enoxaparin followed by admission ..." | ||
| Vol 14, No 1 (2018) | COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015 | Abstract similar documents |
| O. V. Reshetko, A. V. Sokolov, E. V. Rykalina, N. V. Furman | ||
| "... receptors (AMCR), diuretics, oral anticoagulants, emclopidogrel/em increased (p0.05). In the structure ..." | ||
| Vol 14, No 2 (2018) | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. В. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, K. O. Tsukanova | ||
| "... with emclopidogrel/em (up to 5.4%) was registered at the second stage of the study. Over a five-year period bisoprolol ..." | ||
| Vol 16, No 5 (2020) | Treatment of Patients with Acute Coronary Syndrome with ST Segment Elevation in Clinical Practice of the Republic of Karelia: the Results of 10-year Register | Abstract similar documents |
| I. S. Skopets, N. N. Vezikova, A. V. Malafeev, A. N. Malygin, V. A. Litvinova | ||
| "... .8% – emclopidogrel/em, 91.1% – anticoagulants, 91.6% – beta-blockers, 95.6% – statins, 94.2% – angiotensin-converting ..." | ||
| Vol 15, No 4 (2019) | According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention | Abstract similar documents |
| Company Pfizer | ||
| "... , которым показаны антикоагулянты и emантиагреганты/em. ..." | ||
| Vol 8, No 4 (2012) | RAMIPRIL SENSITAZES PLATELETS TO NITRIC OXIDE. IMPLICATION FOR THERAPY IN HIGH-RISK PATIENTS | similar documents |
| S. R. Willoughby, S. Rajendran, W. P. Chan, N. Procter, S. Leslie, E. A. Liberts, T. Heresztyn, Y. Y. Chirkov, J. D. Horowitz | ||
| "... диабетом (СД) или ишемической болезнью сердца (ИБС) имеется emрезистентность/em к NO как на уровне тромбоцитов ..." | ||
| Vol 17, No 1 (2021) | Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease | Abstract similar documents |
| S. K. Zyryanov, S. B. Fitilev, A. V. Vozzhaev, I. I. Shkrebniova | ||
| "... /emclopidogrel/em/oral anticoagulants – 95,7%, statins/ezetimibe – 86,3%, angiotensin-converting enzyme inhibitors ..." | ||
| Vol 8, No 2 (2012): | РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ОСТРОГО КОРОНАРНОГО СИНДРОМА БЕЗ СТОЙКОГО ПОДЪЕМА СЕГМЕНТА ST | Abstract similar documents |
| , , , , , , , , , , , , , , , , | ||
| Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of apixaban together with emCYP/em3A4 ..." | ||
| Vol 17, No 5 (2021) | Pharmacogenetic Aspects of Postoperative Anesthesia with Ketoprofen in Cardiac Surgery Patients | Abstract similar documents |
| T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Z. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. А. Grishina, D. A. Sychev | ||
| "... Aim. Evaluation of the effect of polymorphisms of the emCYP/em2D6, emCYP/em2C8 genes on the efficacy ..." | ||
| Vol 8, No 4 (2012) | ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, I. M. Kuz'mina, A. G. Larin | ||
| "... , более мощных emантиагрегантов/em, а также подробно обсуждается доказательная база практического применения ..." | ||
| Vol 14, No 3 (2018) | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova | ||
| "... статинов и emантиагрегантов/em в зависимости от локализации атеросклеротического поражения и выраженности ..." | ||
| Vol 11, No 2 (2015) | PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST | Abstract similar documents |
| D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii | ||
| "... laboratory control and monitoring are needed, drugs interactions (at the level of emCYP/em3A4, P-gp), management ..." | ||
| Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
| I. S. Yavelov | ||
| "... использовании emантиагрегантов/em у больных, перенесших инфаркт миокарда. ..." | ||
| Vol 8, No 6 (2012) | THE LIS STUDY (LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION). EVALUATION OF DRUG THERAPY. PART 2. INFLUENCE OF PREVIOUS DRUG TREATMENT ON LONG-TERM LIFE PROGNOSIS | Abstract similar documents |
| S. Yu. Martsevich, M. L. Gynzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. U. Drozdova, E. V. Daniels, A. V. Fokina | ||
| "... карт. Результаты. До развития референсного ОИМ основные группы лекарственных препаратов [emантиагреганты/em ..." | ||
| Vol 19, No 5 (2023) | Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease | Abstract similar documents |
| N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev | ||
| "... 1045642, rs1128503), emCYP/em3A5 (rs776746), emCYP/em3A4 (rs35599367) and emCYP/em2J2 (rs890293) genes with residual ..." | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... of nucleotide sequence showed significant deviation: 4 in the ABCG2 gene, 2 in the emCYP/em3A4 gene, and 1 ..." | ||
| Vol 5, No 4 (2009) | GASTROENTEROPATHIES ASSOCIATED WITH ACETYLSALICYLIC ACID: HOW TO IMPROVE SAFETY OF THERAPY | Abstract similar documents |
| A. L. Komarov | ||
| "... другими emантиагрегантами/em, антикоагулянтами, нестероидными противовоспалительными препаратами и ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... атеросклероза периферических артерий с помощью комбинации антикоагулянта – ривароксабана и emантиагреганта/em ..." | ||
| Vol 10, No 3 (2014) | THE CAPABILITIES OF A REGISTER AS A QUALITY CONTROL OF THE PHARMACOTHERAPY IN OUTPATIENTS AT HIGH RISK OF CARDIOVASCULAR COMPLICATIONS (THE "LIS-1" REGISTER) | Abstract similar documents |
| M. L. Ginzburg, S. Y. Martsevich, N. P. Kutishenko, Y. V. Lukina, A. D. Deev | ||
| "... (иРААС) – 35,3%, emантиагреганты/em –15,7%, статины – 1,9%, диуретики – 13% больных. Статистически значимое (с ..." | ||
| Vol 10, No 6 (2014) | CHANGES IN PREHOSPITAL PHARMACOTHERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN 2005-2014 ACCORDING TO THE LIS REGISTER | Abstract similar documents |
| S. Y. Martsevich, M. L. Ginzburg, N. P. Kutishenko, A. V. Zagrebelnyy, I. S. Balashov, L. G. Garkina | ||
| "... динамика в назначении emантиагрегантов/em (13,5% в 2005 г. и 27,4% в 2014 г.), статинов (1,7% и 16 ..." | ||
| 1 - 100 of 143 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
.jpg)
